Anti-Human TNF beta Recombinant Antibody (Pateclizumab) (CAT#: TAB-071)

Figure 1 Observed versus population PK model predicted pateclizumab serum concentration-time profiles.

Dose was given on study days 0, 14, 24, 42, 56, and 70. The empty symbols represent the observed individual serum concentrations at planned sampling times. The solid line represents the population PK model (built based on phase I PK data) predicted median serum concentration-time profile. The shaded band represents model predicted 90% confidence interval of the concentration-time profile for the study population. PK, pharmacokinetic.

Kennedy, W. P., Simon, J. A., Offutt, C., Horn, P., Herman, A., Townsend, M. J., ... & Davis, J. C. (2014). Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Arthritis research & therapy, 16(5), 467.

Figure 1 Anti-Human TNF beta Antibody (TAB-071) in WB

Western blot analysis of TAB-071 was performed with Recombinant Human TNF beta Protein (lane 1, 0.1 μg; lane 2, 0.3 μg; lane 3, 0.6 μg) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-071 and HRP Goat Anti-Human IgG as a secondary antibody. Chemiluminescent detection was performed.

Figure 2 Anti-Human TNF beta Antibody (TAB-071) in ELISA

ELISA analysis of TAB-071 was performed by coating with Recombinant Human TNF beta Protein. Then blocked with BSA, and incubated with Anti-Human TNF beta Antibody (TAB-071). The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 3 Anti-Human TNF beta Antibody (TAB-071) in DB

Antigen: Recombinant human TNF beta protein
Antibody incubation concentration: 2ng/μL.
The secondary antibody: HRP-conjugated goat anti-human IgG